KRAS and liver disorder: EXPEDITION-4 was a phase III multi-center open-label trial to assess the efficacy and safety of antiviral therapy for HCV (combined therapy of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir) for 12 weeks in adults with HCV infection and HCV genotype 1, 2, 3, 4, 5, or 6 and compensated liver disease (with or without cirrhosis) [27].